BioSpace News Archive

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced podium and poster presentations of its SAKURA 3 Phase 3 open-label, long-term safety study of DaxibotulinumtoxinA for Injection (DAXI) for the treatment of glabellar (frown) lines at the 17th Aesthetics & Anti-Aging Medical World Congress (AMWC).

Medtronic plc (NYSE:MDT) today announced results of a study published in JAMA Network Open that demonstrates a reduction in health care utilization and cost for cancer pain patients using targeted drug delivery (TDD) and conventional medical management (CMM) vs. CMM alone.

CPhI & P-MEC China (#CPhIChina and #PMECChina) – co-organized by UBM EMEA, CCCMHPIE, and UBM Sinoexpo – takes place at the Shanghai New International Expo Center (SNIEC) on 18-20th June 2019.

Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce that GeneDesign, Inc. has joined the global organization.

Based on its exclusive license related to photoimmunotherapy, Rakuten Medical Inc., which is developing a cancer therapy to target cancer cells, announced that ASP-1929 received Sakigake designation under the Sakigake Designation System*, which is a Fast Track designation from the Japanese Ministry of Health, Labour, and Welfare as a treatment for head and neck cancer patients.

McKesson Corporation today announced a technology collaboration with Google Cloud that will advance the development of next-generation applications and products, machine learning and artificial intelligence (AI) technologies, and enhanced analytics in support of the company’s strategic growth initiative to transform care delivery and drive profit.

In conjunction with Henry Ford Health System’s April bond offering, Moody’s Investors Service upgraded Henry Ford Health System’s bond rating to A2 with stable outlook, expecting the health system to continue producing increasingly stronger margins and cash flow in the coming year.

Concert Pharmaceuticals, Inc. announced that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office has issued a final written decision in connection with the inter partes review of U.S. Patent No. 9,249,149.

Suicide is the tenth leading cause of death in the United States and the 12th leading cause of death in Massachusetts.

Ascension Ventures, a strategic healthcare venture firm representing thirteen of the nation’s leading non-for-profit health systems, announced today the completion of an investment in Strive Health, a new company launched to fundamentally change the lives of kidney disease patients through early engagement, comprehensive coordinated care, and expanded treatment options.